Learn more →
Back to Expert Scholars
Translational Medicine / 转化医学Oncology Regulatory Science

Mark Ratain

马克·拉坦

MD

🏢University of Chicago Medicine(芝加哥大学医学中心)🌐USA

Leon O. Jacobson Professor of Medicine; Director, Center for Personalized Therapeutics雅各布森医学讲席教授;个体化治疗中心主任

67
h-index
3
Key Papers
3
Awards
3
Key Contributions

👥Biography 个人简介

Mark Ratain is a premier oncology pharmacologist who has challenged dogma in drug dosing and trial design. His advocacy for dose optimization and pragmatic trial approaches has saved costs and improved safety for cancer patients. He is a leading critic of suboptimal dose selection in oncology drug development.

Share:

🧪Research Fields 研究领域

Pharmacology药理学
Dose Optimization剂量优化
Pragmatic Trials实用性临床试验
Oncology Drug Development肿瘤药物研发

🎓Key Contributions 主要贡献

Oncology Dose Optimization

Pioneered research demonstrating that many approved oncology drugs are used at unnecessarily high doses; advocated for dose-optimization studies as part of regulatory approval.

Pragmatic Clinical Trials in Oncology

Developed pragmatic trial designs that reduce barriers to participation and generate real-world relevant evidence for oncology drug approvals.

Pharmacogenomics and Personalized Dosing

Advanced use of pharmacogenomics to tailor drug doses to individual patients, reducing toxicity and improving outcomes in cancer pharmacotherapy.

Representative Works 代表性著作

[1]

Dose Optimization of Anticancer Agents: Are We Asking the Right Questions?

Nature Reviews Clinical Oncology (2021)

Influential critique arguing that oncology drug developers routinely select doses that are too high, causing unnecessary toxicity.

[2]

Sorafenib in Advanced Clear Cell Renal Cell Carcinoma: Pivotal Trial

New England Journal of Medicine (2007)

Co-authored registration trial for sorafenib, demonstrating improved progression-free survival in renal cell carcinoma.

[3]

UGT1A1 Genotyping and Irinotecan Dosing

Journal of Clinical Oncology (2004)

Established pharmacogenomic basis for individualizing irinotecan dosing, influencing FDA label revisions.

🏆Awards & Recognition 奖项与荣誉

🏆American Society of Clinical Pharmacology and Therapeutics (ASCPT) Distinguished Investigator Award
🏆ASCO Statesman Award
🏆University of Chicago Distinguished Service Award

📄Data Sources 数据来源

Last updated: 2026-01-15 | All information from publicly available academic sources

关注 马克·拉坦 的研究动态

Follow Mark Ratain's research updates

留下邮箱,当我们发布与 Mark Ratain(University of Chicago Medicine)相关的新研究或访谈时,我们会通知你。

我们不会泄露你的信息,也不会发送无关内容。随时可以退订。

Explore More Experts

Discover the researchers shaping the future of cancer treatment